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Objective: this study aimed to determine the natural prevalence of variants of tyrosine-
methionine-aspartic acid-aspartic acid (YMDD) motif in patients with chronic hepatitis B 
(cHB), and to explore its relation with demographic and clinical features, hepatitis B virus 
(HBV) genotypes, and HBV DnA levels. 
Methods: A total of 1,042 antiviral treatment naïve cHB patients (including with lamivudine 
[LAM]) in the past year were recruited from outpatient and inpatient departments of six 
centers from December 2008 to June 2010. YMDD variants were analyzed using the HBV drug 
resistance line probe assay (inno-Lipa HBV-Dr). HBV genotypes were detected with polymerase 
chain reaction (Pcr) microcosmic nucleic acid cross-ELisA, and HBV deoxyribonucleic acid 
(DnA) was quantitated with real-time Pcr. All serum samples underwent tests for HBV, HcV, 
and HDV with ELisA.
Results: YMDD variants were detected in 23.3% (243/1042) of cHB patients. YMDD mutation 
was accompanied by L180M mutation in 154 (76.9%) patients. Both wild-type HBV and YMDD 
variant HBV were present in 231 of 243 patients. interestingly, 12 patients had only YiDD and/
or YVDD variants without wild YMDD motif. in addition, 27.2% (98/359) of HbeAg-positive 
patients had YMDD mutations, which was higher than that in HbeAg-negative patients 
(21.2%, 145/683). the incidence of YMDD varied among patients with different HBV genotypes, 
but the difference was not significant. Moreover, the incidence of YMDD in patients with high 
HBV DnA level was significantly higher than that in those with low HBV DnA level.
Conclusion: Mutation of YMDD motif was detectable at a high rate in cHB patients in this 
study. the incidence of YMDD may be correlated with HBeAg and HBV DnA level.
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Introduction
Hepatitis B virus (HBV) is a leading cause of l iver 
diseases worldwide, and china has a high prevalence 
of HBV infection. HBV can replicate through reverse 
transcription using viral ribonucleic acid (rnA) dependent 
deoxyribonucleic acid (DnA) polymerase, which has been a 
target of most current therapeutic approaches for inhibiting 
HBV replication. several nucleos(t)ide analogues (nA) such 
as lamivudine, adefovir, and entecavir have been developed 
for the treatment of chronic hepatitis B (cHB). However, 
prolonged treatment with antiviral drugs is often associated 
with a high incidence of viral resistance. Drug-resistance 
associated with tyrosine-methionine-aspartic acid-aspartic 
acid (YMDD) mutation has become the most important cause 
of treatment failure using nA.1
Gene mutations resulting in lamivudine resistance occur 
particularly in the highly conserved YMDD motif of the 
catalytic domain (c domain) of DnA polymerase.2 substitutions 
of methionine at codon 204 to either isoleucine (rtM204i, YiDD 
variant) or valine (rtM204V, YVDD variant) are the predominant 
mutations causing lamivudine resistance.3,4 the YVDD variant 
is almost always accompanied by an additional rtL180M 
mutation of the B domain.5
Although the presence of drug-resistant strains is closely 
related to the duration of lamivudine treatment, and the 
mutations of YMDD motif are thought to be secondary to 
lamivudine use, it has become increasingly evident that 
YMDD mutations occur naturally and exist in HBV patients 
who did not receive antiviral therapy, particularly in those with 
antibody against hepatitis B e antigen (anti-HBe) in serum.6-13 
it is unknown, however, whether or not pretreatment YMDD 
mutations are selected by lamivudine during treatment.
A test system using the line probe assay (LiPA) has been 
developed for the detection of resistance mutations in the 
HBV polymerase gene.14 LiPA is an useful tool for rapid and 
accurate detection of mutations, which are present in as little 
as 10% of the HBV population.15-17 the present study aimed 
to determine the natural prevalence of YMDD mutation in 
chronic HBV patients in china.
Patients and methods
Patients
in the past year. All patients were negative for HcV and HDV. 
these patients were excluded from the study as no further 
analysis of the viral DnA could have been performed. Blood was 
collected twice from each patient: the first blood sample was used 
for biochemical tests including alanine aminotransferase (ALt) 
aspartate aminotransferase (Ast), alkaline phosphatase (ALP), 
γ-glutamyl transpeptidase (GGt), total protein, albumin, total 
bilirubin and platelet count; the second was stored at -80°c and 
used for HBV drug resistance LiPA and detection of HBV DnA by 
polymerase chain reaction (Pcr). All patients were also evaluated 
for hepatosteatosis by abdominal ultrasonography.
HBV/HCV/HDV serology
HBV DnA was isolated from 200 μL of serum using High Pure 
Viral nucleic Acid Kit (roche). the inno-Lipa HBV Dr v1 assay 
(inno-Lipa; innogenetics, Beijing, Beijing Pason Pharmaceuticals 
inc.) was performed according to the manufacturer’s instructions 
using Hot start taq DnA polymerase (invitrogen – UsA). the 
assay was based on amplification of a part of viral polymerase 
gene by the pre-designed primers and reverse hybridization by 
the probes coated on a strip, and detected the HBV polymerase 
wild-type mutations and known drug-induced mutations 
associated with lamivudine and famciclovir resistance (codons 
180, 204, and 207).
Measurement of serum HBV DNA by real-time PCR
serum and HBV DnA were measured quantitatively by real-
time Pcr (Model 5700, ABi company - UsA) with a lower limit 
of detection of 1 × 103 HBV DnA copies/mL and 1 × 103 copies/μg 
total DnA. 
Detection of HBV genotypes 
HBV genotypes were detected by Pcr-microcosmic nucleic acid 
cross-ELisA. there were 25 patients whose HBV genotyping 
was performed at the Biomedicine Diagnosis and research 
center, Basic Medicine Department of the first Military 
Medical University, and for 1,017 patients HBV genotyping was 
performed in our hospital. 
Statistical analysis 
All quantitative data were presented as mean ± standard 
deviation (sD). Demographic data were analyzed using 
descriptive statistical tests. Mann-Whitney’s U-test, chi-
squared test, and fisher’s exact test were used for comparison 
of groups. the factors included patient age, gender, ALt, 
Ast, ALP, GGt level, HBeAg status, HBV DnA level, alcohol 
consumption, family history of hepatosteatosis, and HBV 
genotype. initially, univariate analyses were conducted. 
then, all factors found to be at least marginally associated 
with the incidence of YMDD mutation (p < 0.15) were tested by 
multivariate analysis using a stepwise logistic model. A p-value 
< 0.05 was considered statistically significant. statistical 
Package for the social sciences (sPss) version 13.0 (sPss inc. – 
chicago, iL, UsA) for Windows was used for statistical analyses.
serum samples were tested for HBV, HcV and HDV using ELisA 
(roche – shanghai, china). 
HBV drug resistance LIPA (Inno-Lipa HBV DR)
A total of 1,042 patients were recruited from outpatient and 
inpatient departments of six centers from December 2008 to June 
2010 (628 patients from the no. 3 People’s Hospital of Zhenjiang, 
215 patients from the no. 2 Hospital of nanjin, 89 patients 
from the first Affiliated Hospital of suzhou University, 56 
patients from the Affiliated Hospital of Yangzhou University, 
29 patients from the People’s Hospital of Wujiang, 25 patients 
from the People’s Hospital of Danyang). Demographic and 
clinical features of these patients are shown in table 1. of these 
patients, 359 were positive for HBeAg, and the remaining were 
HBeAg negative. the diagnosis of cHB was made according to the 
criteria of the national Program for Prevention and treatment of 
Viral Hepatitis.18 Patients had not received antiviral treatment 
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Results
YMDD mutation data of 1042 CHB cases 
YMDD variants were found in 23.3% (243/1042) of HBV patients. 
the demographic and clinical features of the study group are 
summarized in table 1. of 243 patients with YMDD mutations, 
154 (63.4%) had concomitant L180M mutation, and two had 
a mutation at codon 207. Both wild-type and YMDD variant 
carrying HBV were present in 231 of 243 patients. Mixtures 
of YMDD+YVDD, YMDD+YiDD, and YMDD+YVDD+YiDD were 
found in 48, 78, and 118 patients, respectively. in 12 patients, 
only YiDD and/or YVDD variants were observed, and YiDD + 
YVDD, YiDD, and YVDD variants were shown in five, four, and 
three patients, respectively.
Relationship between hepatosteatosis and YMDD mutations
there were 124 patients (11.9%) who had hepatosteatosis 
diagnosed ultrasonographically. in the hepatosteatosis group, 
there were 15 patients whose body mass index (BMi) was 
greater than 30. in addition, there were six patients who had 
a history of alcohol consumption. only two patients with 
hepatosteatosis had a history of alcohol consumption and 
BMi over 30. twenty-six of 124 patients had YMDD variants, 
but there was no significant difference between HBV patients 
with hepatosteatosis and HBV patients with no hepatosteatosis 
(χ2 = 1.837, p = 0.054).
Relationship between HBeAg status and YMDD mutations 
of the 359 patients positive for HBeAg, 98 (27.3%) had 
YMDD mutations. of the 683 patients negative for HBeAg 
but positive for anti-HBe, 145 (21.2%) had YMDD mutations. 
there was a significant difference between these two 
groups in the positivity rate of YMDD mutation (χ2 = 4.846, 
p = 0.028).
YMDD mutations in patients with different HBV genotypes 
Genotypes of these patients included D, c, B, non-classified 
types and mixed forms of cD, cB and DB. YMDD mutations in 
patients with different genotypes are shown in table 2. results 
demonstrated that the YMDD mutations mostly occurred in 
patients with genotype c or its mixed genotypes, accounting 
for 51.4% (536/1042).
Characteristics Total 
(n = 1042)
YMDD variants 
(n = 243, 23.3%)
Without YMDD variants 
(n = 799, 76.7%)
p-value 
Age (years) 42 ± 13 42 ± 14 43 ± 12 0.783
Male 763 (73.2) 173 (71.2) 590 (73.9) 0.414
female 279 (26.8) 70 (28.8) 209 (26.1) 0.414
Alcohol consumption 125 (12.0) 26 (10.7) 99 (12.4) 0.472
family history† 475 (45.6) 105 (43.2) 370 (46.3) 0.325
Hepatosteatosis‡ 124 (11.9) 26 (7.4) 98 (12.2) 0.054
Ast (iU/L) 53 ± 25 56 ± 24 54 ± 23 0.963
ALt (iU/L) 67 ± 26 64 ± 33 69 ± 31 0.955
ALP (iU/L) 102 ± 45 106 ± 46 112 ± 54 0.067
GGt (iU/L) 26 ± 4 25 ± 3 26 ± 3 0.852
cHB, chronic hepatitis B; YMMD, tyrosinemethionine-aspartic acid-aspartic acid; Ast, aspartate aminotransferase; ALt, alanine 
aminotransferase; ALP, alkaline phosphatase; GGt, γ-glutamyl transpeptidase; sD, standard deviation. 
Data are expressed as mean ± sD or as n (%). 
†family history of positive HBsAg including third-generation relatives. 
‡Determined by ultrasonography.
Table 1 - Demographic and clinical features of CHB patients
Genotypes n Patients with YMDD mutations Positive rate (%)
cD 225 51 22.7
cB 156 36 23.1
c 195 47 24.1
D 47 10 21.2
B 109 24 22.1
DB 128 27 21.3 
non-classified types 182 48 26.4
total 1042 243 23.3
YMMD, tyrosinemethionine-aspartic acid-aspartic acid; HBV, hepatitis B virus. 
χ2 = 2.413, p = 0.878
Table 2 - YMDD mutations in patients with different HBV genotype
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Relationship between HBV DNA level and YMDD mutations 
HBV-DnA levels of ≤ 103, > 103 ~ ≤ 105, and > 105 were found in 
16.0% (41/257), 22.9% (131/573) and 29.2% (71/212) of patients 
with YMDD mutations, respectively. there was a significant 
difference in the positivity rate of YMDD mutations between 
patients with HBV DnA level of ≤ 103 and those with HBV DnA 
level of > 105 among different groups (table 3, χ2 = 20.130, 
p = 0.000), suggesting that the HBV DnA level was positively 
correlated with YMDD mutations. Moreover, the HBV-DnA 
level in HBeAg positive patients and HBeAg negative patients 
were 3.47 ± 0.45 × 107 copies/mL and 6.44 ± 1.25 × 105 copies/mL, 
respectively, showing marked difference (t = 4.29, p = 0.03). 
Analysis of factors associated with YMDD mutations
Univariate analysis of individual factors showed that the 
HBV DnA level and the HBeAg status were associated with 
YMDD mutations. there was no association with the other 
factors: patients’ age, gender, ALt, Ast, ALP, GGt level, HBeAg 
status, HBV DnA level, alcohol consumption, family history 
of hepatosteatosis, and HBV genotype. Multivariate analysis 
revealed that HBV DnA level (p = 0.025) and HBeAg status 
(p = 0.043) were also associated with YMDD mutations (table 4).
Relationship between HBV DNA level and HBeAg status
HBV DnA level was associated with HBeAg status by univariate 
analysis (table 5).
Discussion
in this study, the results showed that YMDD variants naturally 
existed in 23.3% of untreated cHB patients, most of whom also 
had wild-type HBV. Previous reports showed that the incidence 
of YMDD variants ranged from 0%~27.7% for asymptomatic 
HBV carriers and 0%~26.9% for cHB patients. these studies 
were mostly from Asian countries including Japan, china, and 
Korea. the discrepancy among these studies may be attributed 
to the relatively small sample sizes, the different methods for 
detection, and the distinct characteristics of subjects such as 
the duration of infection, viral load, viral genotype, and other 
amino acid variations of viral genome. in this study, a well-
characterized commercial assay was used, which can detect 
variants that comprise as little as 10% of the viral population.15 
A recent report investigated the inno-Lipa HBV Dr assay in 
monitoring HBV-infected patients receiving nA treatment, and 
showed that the LiPA test had convincing diagnostic sensitivity 
and accuracy. Moreover, in the present study, a large number 
of subjects were recruited, which makes it possible to obtain a 
more accurate prevalence of YMDD variants existing naturally 
in chinese patients.
in the present study, the majority of YMDD-positive 
patients had both wild-type HBV and YMDD variant carrying 
HBV, which is consistent with other studies.8 interestingly, 
there were 12 patients presenting hybridization only with 
HBV DNA  
(copies/mL)
n YMDD mutations  
(n, %)
≤ 103 257 41 (16.0)
>103~≤ 105 573 131 (22.9)
>105 212 71 (29.2)
YMMD, tyrosinemethionine-aspartic acid-aspartic acid; HBV, 
hepatitis B virus; DnA, deoxyribonucleic acid; χ2 = 20.130, p < 0.001.
Table 3 - YMDD mutations in patients with different 
HBV DNA levels
Factors Category Odds ratio 95% CI p-value
1: ≤ 103 1
HBV DnA levels (copies/mL) 2: > 103 ~ ≤ 105 2.563 0.146-1.386 0.048
3: > 105 4.376 0.375-3.287 0.025
HBeAg status
1: negative 1
2: positive 0.763 0.076-1.438 0.043
ci, confidence interval; p-value by logistic regression analysis; YMMD, tyrosinemethionine-aspartic acid-aspartic acid; HBV, hepatitis B virus; 
DnA, deoxyribonucleic acid.
HBV DNA levels (copies/mL) HBeAg negative  
(n = 683)
HBeAg positive  
(n = 359)
Odds ratio 95% CI p-value 
≤ 103 136 3 1
> 103 ~ ≤ 105 349 140 6.387 2.176-23.153 0.012
> 105 198 216 9.267 3.175-33.176 0.001
ci, confidence interval; p-value by logistic regression analysis; YMMD, tyrosinemethionine-aspartic acid-aspartic acid; HBV, hepatitis B virus; 
DnA, deoxyribonucleic acid.
Table 4 - Multivariate analysis of factors associated with YMDD mutation
Table 5 - Analysis of the relationship between HBV DNA levels and HBeAg status
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YVDD and/or YiDD variants. LiPA assay indicated that wild-
type virus was either absent or represented only a minor 
population in these patients. one of the possibilities for the 
presence of mutant strains may be the acquisition of samples 
from lamivudine-resistant subjects. Medical records of patients 
showing hybridization only with YVDD and/or YiDD variants 
were carefully re-examined, but no further information related 
to the source or the duration of infection could be identified. 
they were known to be the only HBV-infected member of their 
families.
Kobayashi et al.19 and Da silva et al.20 found that anti-
HBe was positive in all patients with YMDD mutations, and 
Ye et al.21 noted that anti-HBe was positive in most patients 
with YMDD mutations and considered that YMDD mutations 
might occur more easily if mutations take place in the pre-c-
zone. in this study, the findings revealed that the incidence 
of YMDD mutations was 21.2% in patients negative for HBeAg 
and 27.2% in patients positive for HBeAg showing significant 
difference. Moreover, multivariate analysis revealed that the 
HBeAg status (p = 0.043) was associated with YMDD mutations. 
these findings were not in accordance with those of Kobayashi 
et al.5 and Ye et al.21 
some researchers19,22 reported a positive correlation 
between high serum HBV DnA level and incidence of 
YMDD mutations. the present results were consistent 
with these studies that, in terms of incidence of YMDD 
mutations, a significant difference was found among 
patients with different serum HBV DnA levels, suggesting 
that the HBV DnA level might have a positive correlation 
with YMDD mutations. Moreover, the serum HBV-DnA level 
in HBeAg positive patients (3.47 ± 0.45 × 107 copies/mL) 
was dramatically different from that in HBeAg negative 
patients (6.44 ± 1.25 × 105 copies/mL). Univariate analysis of 
the relationship between HBV DnA level and HBeAg status 
revealed that HBV DnA level was associated with HBeAg 
status. thus, it is possible that the difference of YMDD 
mutations of HBeAg system may be correlated with viral 
loads of HBV.
the correlation between HBV genotypes and YMDD 
mutations (pre or post-treatment) remains unclear and 
conflicting data have been reported.23-26 the present results 
revealed a difference in the incidence of HBV YMDD wild 
mutational strains between HBV genotypes c, D, non-
classified types, and mixed genotypes of cD and cB. Most of 
the mutations (56.4%) occurred in patients with genotype c 
or its mixed forms, partially because patients with genotype 
c account for the majority of cHB patients in china. Although 
there was no significant difference among these genotypes, 
the relationship between YMDD mutations and HBV 
genotypes could not be ruled out, as the sample size was 
relatively small. 
one limitation of the present study was the lack of cloning 
and sequencing of samples carrying YMDD variants, in 
order to evaluate the dominance of different quasispecies, 
and to reconfirm the LiPA findings. Detailed evaluation 
of quasispecies was not one of the aims of this study. the 
findings were validated by using a well-evaluated commercial 
assay and repeatedly testing the samples that had unusual 
results.27,28 
in conclusion, naturally occurring YMDD variants are 
detectable in the majority of cHB patients without antiviral 
therapy. incidence of YMDD mutation may be correlated with 
HBeAg and HBV DnA level.
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